-
EXP CELL RES 2024 10.1016/j.yexcr.2024.114248
Exosomal miR-155-5p drives ibrutinib resistance in B-cell lymphoma
Park, B; Choi, ME; Ryu, KJ; Park, C; Choi, M; Yoon, SE; Kim, WS; Kim, HH; Hong, JY; Kim, SJ
View PubMed
-
CANCER TREAT REV 2024 10.1016/j.ctrv.2024.102793
Peripheral T-cell lymphoma: From biology to practice to the future
O'Connor, OA; Ma, H; Chan, JYS; Kim, SJ; Yoon, SE; Kim, WS
View PubMed
-
BLOOD 2024 10.1182/blood.2023023419
CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis
Kim, J; Cho, J; Lee, MH; Yoon, SE; Kim, WS; Kim, SJ
View PubMed
-
ANN HEMATOL 2024 10.1007/s00277-024-05902-w
Long-term survival outcomes of 'watch and wait' in patients with bronchus-associated lymphoid tissue lymphoma: a multicenter real-world data analysis in Korea
Kwak, K; Yoo, KH; Choi, YS; Park, Y; Kim, BS; Yoon, SE; Kim, WS; Kang, KW; Kim, SJ
View PubMed
-
CANCER RES TREAT 2024 10.4143/crt.2023.869
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Yoon, SE; Shin, SH; Nam, DK; Cho, J; Kim, WS; Kim, SJ
View PubMed
-
ANN HEMATOL 2024 10.1007/s00277-024-05739-3
Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma
Yoon, SE; Cho, H; Berning, P; Cho, J; Kim, HY; Yoon, DH; Schmit, N; Kim, SJ; Kim, WS
View PubMed
-
ANN LAB MED 2024 10.3343/alm.2023.0388
Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
Kim, SJ; Yoon, SE; Kim, WS
View PubMed
-
ACTA HAEMATOL-BASEL 2024 10.1159/000537962
Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma: Real-World Experience
Choi, DH; Yoon, SE; Cho, JH; Kim, SJ; Kim, WS
View PubMed
-
CANCER RES TREAT 2024 10.4143/crt.2023.1042
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Lee, JY; Kwon, JH; Hur, JY; Yi, JH; Lee, JH; Cho, H; Do, YR; Jo, JC; Kang, HJ; Koh, Y; Lee, WS; Lim, SN; Yoon, SE; Kim, SJ; Lee, JO
View PubMed
-
HEMASPHERE 2024 10.1002/hem3.33
Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
Cho, H; Kim, K; Yoon, SE; Jung, SH; Lee, JJ; Moon, JH; Cho, HJ; Lee, HS; Kang, KW; Kim, SY; Eom, HS; Mun, YC; Park, YH; Yoon, SS; Do, YR; Lee, WS; Min, CK; Yoon, DH
View PubMed
-
ANN HEMATOL 2024 10.1007/s00277-024-05615-0
Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis
Yi, JH; Park, SS; Min, CK; Eom, HS; Byun, JM; Koh, Y; Yoon, SS; Lee, JH; Jung, SH; Lee, JJ; Yoon, SE; Woo, SY; Kim, K
View PubMed
-
FRONT ONCOL 2023 10.3389/fonc.2023.1194315
The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
Yoon, SE; Park, S; Cho, J; Ryu, KJ; Yandava, B; Lee, S; Kim, SJ; Kim, WS
View PubMed
-
FRONT ONCOL 2023 10.3389/fonc.2023.1230629
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
Kim, SJ; Jo, JC; Yoon, DH; Yang, DH; Yoon, SE; Lee, GW; Kong, JH; Park, Y; Kang, KW; Lee, HS; Oh, SY; Shin, HJ; Lee, WS; Choi, YS; Jeong, SH; Kim, MK; Kang, HJ; Yi, JH; Lim, SN; Yhim, HY; Do, YR; Yun, HJ; Eom, HS; Lee, MH; Suh, C; Kim, WS
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.1658
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
Kim, J; Cho, JHY; Yoon, SE; Kim, WS; Kim, SJ
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.1535
Case Report of Erdheim-Chester Disease Successfully Treated with Pegylated Interferon: A Single-Center Experience
Lim, Y; Yoon, SE; Cho, J; Kim, D; Jung, CW
View PubMed
-
CANCER MANAG RES 2023 10.2147/CMAR.S407837
Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
Lee, YP; Yoon, SE; Cho, J; Ko, YH; Oh, D; Ahn, YC; Kim, WS; Kim, SJ
View PubMed
-
CANCER MED-US 2023 10.1002/cam4.6268
A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma
Lee, H; Yoon, SE; Kim, SJ; Kim, WS; Cho, JH
View PubMed
-
BLOOD 2023 10.1182/blood.2022018831
The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma
Yoon, SE; Kang, W; Choi, S; Park, Y; Chalita, M; Kim, H; Lee, JH; Hyun, DW; Ryu, KJ; Sung, H; Lee, JY; Bae, JW; Kim, WS; Kim, SJ
View PubMed
-
ANN HEMATOL 2023 10.1007/s00277-023-05182-w
Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma
Jeon, Y; Yoon, SE; Cho, JH; Kim, SJ; Kim, WS
View PubMed
-
FRONT IMMUNOL 2023 10.3389/fimmu.2023.1139980
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
Yang, J; Won, G; Baek, JY; Lee, YH; Kim, H; Huh, K; Cho, SY; Kang, CI; Chung, DR; Peck, KR; Lee, KW; Park, JB; Yoon, SE; Kim, SJ; Kim, WS; Yim, MS; Kim, K; Hyeon, S; Kim, BC; Lee, YK; Ko, JH
View PubMed
-
CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2022.10.010
Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea
Kim, HR; Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K
View PubMed
-
SEMIN HEMATOL 2023 10.1053/j.seminhematol.2022.10.002
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Tse, E; Fox, CP; Glover, A; Yoon, SE; Kim, WS; Kwong, YL
View PubMed
-
FRONT ONCOL 2023 10.3389/fonc.2023.1109715
In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
Kim, JJ; Kim, HY; Choi, Z; Hwang, SY; Jeong, H; Choi, JR; Yoon, SE; Kim, WS; Kim, SH; Kim, HJ; Shin, SY; Lee, ST; Kim, SJ
View PubMed
-
CANCER-AM CANCER SOC 2023 10.1002/cncr.34698
TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients
Cho, J; Kim, E; Yoon, SE; Kim, SJ; Kim, WS
View PubMed
-
FRONT ONCOL 2023 10.3389/fonc.2022.1071281
Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
Jeong, SY; Yoon, SE; Cho, D; Kang, ES; Cho, J; Kim, WS; Kim, SJ
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.015
A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum beta-2 Microglobulin to PINK
Kang, S; Cho, H; Kim, S; Lee, K; Kang, EH; Park, JS; Lee, YS; Park, CS; Go, H; Huh, J; Ryu, JS; Lee, SW; Kim, SJ; Kim, WS; Yoon, SE; Ko, YH; Suh, C
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.017
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
Kim, SJ; Kim, YJ; Yoon, SE; Ryu, KJ; Park, B; Park, D; Cho, D; Kim, HY; Cho, J; Ko, YH; Park, WY; Kim, WS
View PubMed
-
VIRCHOWS ARCH 2023 10.1007/s00428-023-03493-x
Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma
Lee, J; Han, JH; Lee, CH; Park, HS; Min, SK; Lee, H; Cho, U; Yoon, SE; Kim, SJ; Kim, WS; Cho, JH
View PubMed
-
INT J HEMATOL 2022 10.1007/s12185-022-03525-3
A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea
Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K
View PubMed
-
BLOOD ADV 2022 10.1182/bloodadvances.2021006305
CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
Cho, J; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS
View PubMed
-
CL LYMPH MYELOM LEUK 2022 10.1016/j.clml.2022.07.009
Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma
Yoon, SE; Cho, J; Kim, YJ; Kim, SJ; Kim, WS
View PubMed
-
BLOOD CANCER J 2022 10.1038/s41408-022-00755-w
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
Jung, SH; Kim, K; Yoon, SE; Moon, JH; Kim, D; Kim, HJ; Kim, MK; Ha Kim, K; Lee, HJ; Lee, JH; Kim, SH; Yoo, KH; Lee, JH; Lee, JJ
View PubMed
-
J ONCOL 2022 10.1155/2022/2263217
Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis
Lee, YP; Lee, MS; Yoon, SE; Cho, JH; Bang, YH; Shim, JH; Kim, WS; Kim, SJ
View PubMed
-
ANN LAB MED 2022 10.3343/alm.2022.42.5.558
Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
Kim, HY; Yoo, IY; Lim, DJ; Kim, HJ; Kim, SH; Yoon, SE; Kim, SJ; Cho, D; Kim, K
View PubMed
-
ANN HEMATOL 2022 10.1007/s00277-022-04805-y
Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma
Lee, YP; Yoon, SE; Cho, J; Ko, YH; Jo, H; Kim, SJ; Kim, WS
View PubMed
-
CANCER RES TREAT 2022 10.4143/crt.2021.752
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
Yoon, SE; Kim, YJ; Shim, JH; Park, D; Cho, J; Ko, YH; Park, WY; Mun, YC; Lee, KE; Cho, D; Kim, WS; Kim, SJ
View PubMed
-
J CANCER 2022 10.7150/jca.69639
Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma
Bang, YH; Shim, JH; Ryu, KJ; Kim, YJ; Choi, ME; Yoon, SE; Cho, J; Park, B; Park, WY; Kim, WS; Kim, SJ
View PubMed
-
HEMATOL ONCOL 2022 10.1002/hon.2970
Promising clinical efficacy and acceptable safety profile of sequential P-GEMOX and radiotherapy for localized ENKTL
Yoon, SE; Kim, WS
View PubMed
-
BONE MARROW TRANSPL 2022 10.1038/s41409-022-01605-w
Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis
Yoon, SE; Jo, H; Kang, ES; Cho, D; Cho, J; Kim, WS; Kim, SJ
View PubMed
-
J NEURO-ONCOL 2021 10.1007/s11060-021-03909-1
Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma
Kim, N; Lim, DH; Yoon, SE; Kim, SJ; Kim, WS
View PubMed
-
BLOOD CANCER J 2021 10.1038/s41408-021-00595-0
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
Kang, D; Yoon, SE; Shin, D; Lee, J; Hong, YS; Lee, SK; Lee, JE; Park, YH; Ahn, JS; Guallar, E; Kim, WS; Lee, J; Kim, SJ; Cho, J
View PubMed
-
BLOOD CANCER J 2021 10.1038/s41408-021-00577-2
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT
Cho, HJ; Jung, SH; Jo, JC; Lee, YJ; Yoon, SE; Park, SS; Kim, DY; Shin, HJ; Mun, YC; Yi, JH; Kim, HJ; Kim, DJ; Lee, HS; Bae, SH; Hong, CM; Jeong, SY; Min, JJ; Sohn, SK; Min, CK; Kim, K; Lee, JJ; Moon, JH
View PubMed
-
ANN LAB MED 2021 10.3343/alm.2021.41.6.598
Aberrant Loss of Surface CD3 and TCR gamma delta Expression in Relapsed Hepatosplenic T-cell Lymphoma
Lee, B; Lim, DJ; Heo, WY; Yoon, SE; Kim, HY; Kim, HJ; Kim, SH; Cho, D
View PubMed
-
LEUKEMIA LYMPHOMA 2021 10.1080/10428194.2021.1971220
Prognostic significance of serum beta 2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified
Kim, HD; Cho, H; Sohn, BS; Park, CS; Huh, J; Ryu, JS; Lee, SW; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS; Suh, C
View PubMed
-
CANCER COMMUN 2021 10.1002/cac2.12212
Prognostic value of single-nucleotide polymorphisms for extranodal natural killer/T-cell lymphoma: the identification of risk factors in the molecular era
Yoon, SE; Kim, WS
View PubMed
-
CANCER MANAG RES 2021 10.2147/CMAR.S330308
Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma
Lim, CH; Yoon, SE; Kim, WS; Lee, KH; Kim, SJ
View PubMed
-
BMC CANCER 2021 10.1186/s12885-021-08695-7
Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
Cho, J; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS
View PubMed
-
ANN HEMATOL 2021 10.1007/s00277-021-04558-0
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
Kim, WS; Oki, Y; Kim, SJ; Yoon, SE; Ardeshna, KM; Lin, Y; Ruan, J; Porcu, P; Brammer, JE; Jacobsen, ED; Yoon, DH; Suh, C; Suarez, F; Radford, J; Budde, LE; Kim, JS; Bachy, E; Lee, HJ; Bollard, CM; Jaccard, A; Kang, HJ; Inman, S; Murray, M; Combs, KE; Lee, DIY; Advani, R; Gunter, KC; Rooney, CM; Heslop, HE
View PubMed
-
INT J HEMATOL 2021 10.1007/s12185-021-03179-7
Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia
Lee, YP; Yoon, SE; Song, YQ; Kim, SJ; Yoon, DH; Chen, TY; Koh, YI; Kang, KW; Lee, HS; Wei, KTK; Lim, ST; Poon, M; Irawan, C; Zhao, WL; Do, YR; Lee, MH; Ng, SC; Lee, WS; Guo, Y; Zhang, HL; Kang, HJ; Yun, HJ; Kim, HJ; Lung, DTC; Kwak, JY; Han, JJ; Mun, YC; Oh, SY; Shim, H; Kwon, JH; Sohn, BS; Park, SK; Jo, JC; Ko, YH; Jun, Z; Kim, WS
View PubMed
-
J NEURO-ONCOL 2021 10.1007/s11060-021-03815-6
Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy
Kim, N; Lim, HD; Yoon, SE; Kim, SJ; Kim, WS
View PubMed
-
J NEUROIMMUNOL 2021 10.1016/j.jneuroim.2021.577564
Increased proportion of CD20+T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report
Lee1, JK; Kwon, S; Han, JH; Yoon, SE; Kim, BJ; Kang, ES
View PubMed
-
KOREAN J INTERN MED 2021 10.3904/kjim.2019.367
Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia
Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
View PubMed
-
CANCER MANAG RES 2021 10.2147/CMAR.S309092
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ
View PubMed
-
EXP HEMATOL ONCOL 2021 10.1186/s40164-021-00224-3
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas
Yoon1, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS
View PubMed
-
FRONT ONCOL 2021 10.3389/fonc.2021.628807
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Lee1, B; Lee, H; Cho, J; Yoon, SE; Kim, SJ; Park, WY; Kim, WS; Ko, YH
View PubMed
-
SCI REP-UK 2021 10.1038/s41598-021-85332-0
Metabolic activity of extranodal NK/T cell lymphoma on F-18-FDG PET/CT according to immune subtyping
Lim1, CH; Yoon, SE; Kim, SJ; Cho, J; Ko, YH; Lee, KH; Kim, WS
View PubMed
-
J CANCER 2021 10.7150/jca.55553
Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis
Lee1, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ
View PubMed
-
J CANCER 2021 10.7150/jca.54434
Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months
Yoon1, SE; Cho, J; Kim, WS; Kim, SJ
View PubMed
-
J HEPATOL 2021 10.1016/j.jhep.2020.08.010
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Kim1, CG; Kim, C; Yoon, SE; Kim, KH; Choi, SJ; Kang, B; Kim, HR; Park, SH; Shin, EC; Kim, YY; Kim, DJ; Chung, HC; Chon, HJ; Choi, HJ; Lim, HY
View PubMed
-
CANCERS 2020 10.3390/cancers12123548
Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma
Ryu1, KJ; Lee, JY; Choi, ME; Yoon, SE; Cho, J; Ko, YH; Shim, JH; Kim, WS; Park, C; Kim, SJ
View PubMed
-
BLOOD ADV 2020 10.1182/bloodadvances.2020002814
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score
Yhim1, HY; Eshet, Y; Metser, U; Lim, CH; Lajkosz, K; Isaev, K; Cooper, M; Prica, A; Kukreti, V; Bhella, S; Lang, N; Lee, KH; Xu, W; Hodgson, D; Tsang, R; Yoon, SE; Kim, SJ; Kim, WS; Crump, M; Kuruvilla, J; Kridel, R
View PubMed
-
BLOOD 2020 10.1182/blood.2020005026
Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma
Kim1, H; Jeong, H; Yamaguchi, M; Sohn, I; Yoon, SE; Byeon, S; Hur, JY; Koh, Y; Yoon, SS; Kim, EJ; Oguchi, M; Miyazaki, K; Taguchi, S; Yoon, DH; Cho, J; Ko, YH; Kim, SJ; Suzuki, R; Kim, WS
View PubMed
-
BMC CANCER 2020 10.1186/s12885-020-07317-y
Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
Song1, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ
View PubMed
-
SCI REP-UK 2020 10.1038/s41598-020-68310-w
Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era
Song1, GY; Yoon, SE; Kim, SJ; Kim, JS; Koh, Y; Moon, JH; Oh, SY; Lee, HS; Shin, HJ; Do, YR; Lee, WS; Kim, DS; Park, Y; Yhim, HY; Yang, DH
View PubMed
-
KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.396
Asian variant of intravascular large B-cell lymphoma a comparison of clinical features based on involvement of the central nervous system
Yoon1, SE; Kim, WS; Kim, SJ
View PubMed
-
ANN HEMATOL 2020 10.1007/s00277-020-04005-6
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
Yoon1, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS
View PubMed
-
ANN HEMATOL 2020 10.1007/s00277-020-04008-3
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas
Hur1, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS
View PubMed
-
CYTOKINE 2020 10.1016/j.cyto.2020.155048
Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma
Yi1, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ
View PubMed
-
ANN HEMATOL 2020 10.1007/s00277-020-04083-6
A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study
Yoon1, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ
View PubMed
-
MODERN PATHOL 2020 10.1038/s41379-019-0392-8
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
Cho1, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS
View PubMed
-
PSYCHO-ONCOL 2020 10.1002/pon.5265
Impact of fear of cancer recurrence on survival among lymphoma patients
Kim1, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J
View PubMed
-
BMC CANCER 2020 10.1186/s12885-020-6612-2
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
Cho1, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ
View PubMed
-
J Cancer 2019 10.7150/jca.30355
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
View PubMed
-
BMC UROL 2019 10.1186/s12894-019-0463-7
A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer
Yoon1, SE; Kim, Y; Cho, J; Kang, M; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Lee, SJ; Park, SH
View PubMed
-
J Cancer 2019 10.7150/jca.29106
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
View PubMed
